Fidelity MSCI Information Technology Index ETF (ARCA: FTEC)

Últimas noticias sobre Fidelity MSCI Information Technology Index ETF (ARCA:FTEC)

Fidelity MSCI Information Technology Index ETF

Technology

Industrials

Communication Services

Financial Services

Other

Basic Materials

The fund invests at least 80% of assets in securities included in the funds underlying index. The funds underlying index is the MSCI USA IMI Information Technology 25/50 Index, which represents the performance of the information technology sector in the U.S. equity market. It may or may not hold all of the securities in the MSCI USA IMI Information Technology 25/50 Index. The fund is non-diversified.

Apple Inc

Microsoft Corp

NVIDIA Corporation

Broadcom Inc

Salesforce Inc

Adobe Inc

Advanced Micro Devices Inc

Oracle Corp

Accenture Plc Class A

Cisco Systems Inc

Government

News

Regulations

Tech

Media

AAPL

AMZN

FTEC

NVDA

TSLA

Donald Trump asume la presidencia y surgen dudas sobre las regulaciones de semiconductores. Nvidia sube un 138% en 12 meses.

Donald Trump, Nvidia y la IA: Impacto en las regulaciones tecnológicas

Olympian Motors amplía su asociación con Nvidia para crear la Plataforma Olympus, una solución modular de IA para vehículos eléctricos.

Olympian Motors y Nvidia colaboran para desarrollar una plataforma de IA modular para vehículos eléctricos

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $139.67, a high estimate of $149.00, and a low estimate of $135.00. Witnessing a positive shift, the current average has risen by 1.95% from the previous average price target of $137.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666047_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Abbott Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Abbott Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Abbott Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Abbott Laboratories analyst ratings.</strong></a></p>
<h2>About Abbott Laboratories</h2>
<p>Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.</p>
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>4.85%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Abbott Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>15.48%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Abbott Laboratories's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>4.16%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Abbott Laboratories's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>2.23%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.38</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Deep Dive Into Abbott Laboratories Stock: Analyst Perspectives (6 Ratings)

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $254.0, a high estimate of $280.00, and a low estimate of $213.00. Highlighting a 1.6% decrease, the current average has fallen from the previous average price target of $258.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666038_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Travelers Companies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$268.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$225.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$213.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$268.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$278.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$278.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$259.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$217.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Robert Farnam</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Neutral</td>
<td>$280.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Travelers Companies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travelers Companies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Travelers Companies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Travelers Companies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Travelers Companies analyst ratings.</strong></a></p>
<h2>Delving into Travelers Companies's Background</h2>
<p>Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance. Travelers derives 6% of its premiums from foreign markets.</p>
<h3>Travelers Companies: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Travelers Companies showcased positive performance, achieving a revenue growth rate of <strong>11.93%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Travelers Companies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>10.5%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Travelers Companies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.76%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Travelers Companies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.95%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Travelers Companies's debt-to-equity ratio surpasses industry norms, standing at <strong>0.29</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Travelers Companies Stock: Analyst Perspectives (9 Ratings)

<p>Ratings for Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.8, a high estimate of $23.00, and a low estimate of $17.00. Marking an increase of 20.58%, the current average surpasses the previous average price target of $17.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666029_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Envista Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Underperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$23.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Envista Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Envista Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Envista Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Envista Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Envista Holdings analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Envista Holdings</h2>
<p>Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products &amp; Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment &amp; Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.</p>
<h3>Unraveling the Financial Story of Envista Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Envista Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-4.8%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Envista Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.36%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Envista Holdings's ROE excels beyond industry benchmarks, reaching <strong>0.27%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Envista Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.15%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Envista Holdings's debt-to-equity ratio is below the industry average. With a ratio of <b>0.51</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVST

5 Analysts Have This To Say About Envista Holdings

<p>In the last three months, 8 analysts have published ratings on BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $45.75, a high estimate of $50.00, and a low estimate of $42.00. Surpassing the previous average price target of $41.00, the current average has increased by 11.59%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666019_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive BankUnited. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BankUnited. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of BankUnited compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for BankUnited's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of BankUnited's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BKU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BankUnited analyst ratings.</strong></a></p>
<h2>All You Need to Know About BankUnited</h2>
<p>BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located primarily throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.</p>
<h3>BankUnited: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> BankUnited's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>5.96%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> BankUnited's net margin excels beyond industry benchmarks, reaching <strong>23.58%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> BankUnited's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.2%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> BankUnited's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> BankUnited's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.53</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BankUnited Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

<p>Throughout the last three months, 16 analysts have evaluated Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Comerica, revealing an average target of $73.75, a high estimate of $85.00, and a low estimate of $64.00. Witnessing a positive shift, the current average has risen by 4.24% from the previous average price target of $70.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666011_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Comerica. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Comerica. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Comerica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Comerica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Comerica's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comerica analyst ratings.</strong></a></p>
<h2>Get to Know Comerica Better</h2>
<p>With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.</p>
<h3>Financial Milestones: Comerica's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Comerica's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-9.49%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Comerica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.82%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Comerica's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.78%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Comerica's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.97</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Comerica Through 16 Analysts

Trading Ideas

ALUR

Allurion Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.54%

SKBL

Skyline Builders Group Shares Halted On Circuit Breaker To The Upside

<p><a href="https://x.com/chrispavlovski/status/1882532095601545299" title="https://x.com/chrispavlovski/status/1882532095601545299">https://x.com/chrispavlovski/status/1882532095601545299</a></p>


Rumble CEO Chris Pavlovski Posts On X "Rumble Wallet is coming — confirmed. This is a massive internal project which creates a new way for creators to transact."

<p>Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.</p>
<p>Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.</p>


Biotech

General

Allurion Announces Clinical Study Combining Allurion Program And GLP-1 Agonists To Improve Muscle Mass, Studies Show 5.6% Muscle Gain And 14% Weight Loss Over 4 Months With Allurion Balloon; In Another Study Of 167 Patients, Patients Treated With The Allurion Balloon Experienced A Weight Reduction Of 15.7% With No Change In Muscle Mass.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Decentralized Perpetuals Exchanges (DEXs): A Comprehensive Guide To The Future Of Crypto Trading

<p><strong>Lightbridge Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) shares are trading higher Thursday after the company announced a collaboration agreement with<strong> Oklo Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>).</p>
<p><strong>What To Know</strong>: Lightbridge and Oklo entered into a non-binding Memorandum of Understanding (MOU) on Wednesday to explore joint opportunities in nuclear fuel development, according to a new regulatory filing.</p>
<p>The MOU outlines plans for a feasibility study to evaluate co-locating a Lightbridge commercial-scale fuel fabrication facility at Oklo's proposed commercial fuel fabrication site. The companies will also explore opportunities for collaboration on reprocessing and recycling spent uranium-zirconium fuel. </p>
<p>Lightbridge and Oklo shares have soared in recent months, driven by increased optimism around nuclear. Multiple big tech companies have signed deals with nuclear power startups in an effort to keep up with rising energy demands of AI data centers.</p>
<h3 class="wp-block-heading">How To Buy LTBR Stock</h3>
<p>By now you're likely curious about how to participate in the market for Lightbridge &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. In the case of Lightbridge, which is trading at $9.9 as of publishing time, $100 would buy you 10.1 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>LTBR Price Action:</strong> Lightbridge shares were up 40.4% at $10.14 at the time of publication Thursday, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23150812/Screenshot-2025-01-23-at-15.07.34-1024x577.png" alt="" class="wp-image-747667" style="width:433px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23150812/Screenshot-2025-01-23-at-15.07.34-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23150812/Screenshot-2025-01-23-at-15.07.34-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23150812/Screenshot-2025-01-23-at-15.07.34-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23150812/Screenshot-2025-01-23-at-15.07.34.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/25/01/43174150/johnson-johnsons-medtech-momentum-expected-to-rebound-in-2025-despite-current-hurdles-analyst">Johnson &amp; Johnson&#8217;s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst</a></strong></li>
</ul>
<p><em><em>This illustration was generated using artificial intelligence via Midjourney.</em></em></p>


Movers

LTBR

OKLO

Lightbridge Stock Is Surging Today: What's Going On?

<p>The fintech ecosystem is accelerating at such a rapid pace that only the ongoing artificial intelligence boom has been capable of stealing investor attention away from the sprawling financial technology space.&nbsp;</p>
<p>According to McKinsey research, the fintech industry's revenues are expected to grow <a href="https://www.mckinsey.com/industries/financial-services/our-insights/fintechs-a-new-paradigm-of-growth" target="_blank" rel="noreferrer noopener">nearly three times faster</a> than the traditional banking sector between 2022 and 2028. Additionally, the potential 15% revenue growth of the fintech industry over the next five years could significantly outpace the 6% anticipated for the traditional banking sector. </p>
<p>These figures suggest that fintech is on course to become a dominant player throughout the world of finance over the coming years, and we can already see evidence of wholesale changes occurring in real time.&nbsp;</p>
<p>2025 is set to be a key year in the growth of the <a href="https://www.benzinga.com/fintech/25/01/42818294/how-fintech-must-evolve-to-meet-the-needs-of-techs-new-wealth">fintech landscape</a>. According to Capgemini's World Payment Report 2025, digital wallets are not only the fastest-growing alternative to card payments today, but they're forecasted to <a href="https://www.thebanker.com/Digital-wallet-transactions-set-to-grow-while-card-payments-shrink-1726151109" target="_blank" rel="noreferrer noopener">handle 61% of total eCommerce payments</a> and 46% of in-store payments by 2027. </p>
<p>Digital transactions rallied from a total of $802 billion in 2023 to an <a href="https://www.eposnow.com/us/resources/payment-trends/" target="_blank" rel="noreferrer noopener">estimated $929.8 billion</a> in 2024, making 2025 a prime candidate to surpass $1 trillion for the first time. </p>
<p>These fintech trends are set to resonate strongly on Wall Street, and we could see some of the sector's most innovative stocks rally off the back of market growth throughout the year ahead. With this in mind, let's take a look at three high-potential fintech stocks for investors to pick up in 2025:&nbsp;</p>
<h2 class="wp-block-heading">1. PayPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)</h2>
<ol>
<li></li>
</ol>
<p>It's impossible to consider the brightest fintech stocks on Wall Street without looking to PayPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>). The market leader has more than 25 years of experience in the sector and operates a leading payments platform that benefits both merchants and consumers.&nbsp;</p>
<p>With around 432 million users, PayPal's market share makes the stock a formidable player in an industry that's populated by so many startups vying for attention.&nbsp;</p>
<p>In 2024, PayPal's stock rallied more than 44%, and its innovation pipeline and strong usage figures are set to push the company higher amid a wider fintech market rally.&nbsp;</p>
<p>Crucially, last year saw PayPal launch Ad Business, an innovative new service that empowers advertisers to tap into the firm's <a href="https://www.exchangewire.com/blog/2024/10/14/paypal-launches-ad-business-meta-expands-ad-placement-controls-and-brings-ai-chatbot-to-uk-privacy-certification-for-ad-tech-in-the-works/" target="_blank" rel="noreferrer noopener nofollow">masses of data</a> on user payment transaction data across its platforms. </p>
<p>This extra revenue stream plus PayPal's <a href="https://www.infoq.com/news/2024/10/paypal-cosmosai-llm-genai/" target="_blank" rel="noreferrer noopener">utility of generative AI tools</a> in recent months to boost support for the creation of large-language models (LLMs) within its growing Cosmos.AI platform highlights a firm that's focused on growth. </p>
<p>Of course, the rise of rivals like Apple Pay, Cash App, Square, and Adyen can all threaten PayPal's dominance in the future, but if it continues to protect its market share, PYPL will be a stock that deserves attention in 2025.&nbsp;</p>
<h2 class="wp-block-heading">2. SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)</h2>
<ol start="2">
<li></li>
</ol>
<p>SoFi's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) rapid growth has propelled the firm into a high-potential prospect for the fintech industry.&nbsp;</p>
<p>With growth of 94.4% in 2024, SoFi emerged as one of the stars of Wall Street last year, and looking at the open banking firm's acquisition rates, it's easy to see why.&nbsp;</p>
<p>In 2020, the lending, investing, saving, loan refinancing, and real estate planning platform had over 1 million members. Today, SoFi has more than 10 million, representing an astonishing rate of growth in a relatively short period.&nbsp;</p>
<p>For the third quarter of 2024, SoFi reported record adjusted <a href="https://www.businesswire.com/news/home/20241029800153/en/SoFi-Technologies-Reports-Net-Revenue-of-697-Million-and-Net-Income-of-61-Million-for-Q3-2024-Demonstrating-Durable-Growth-and-Strong-Returns" target="_blank" rel="noreferrer noopener nofollow">net revenue growth of 30%</a> to $697.1 million and a 64% combined growth in financial services and tech platform segments. </p>
<p>SoFi Technologies has also shown a strong pedigree in its commitment to embracing artificial intelligence, and the implementation of AI features like transactional fraud detection and improved payment efficiency point to a company that's ready to scale further in 2025.&nbsp;</p>
<h2 class="wp-block-heading">3. Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>)</h2>
<ol start="3">
<li></li>
</ol>
<p>With a market capitalization of around $1.5 billion, Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) is a fintech platform that's ripe for growth in the year ahead.&nbsp;</p>
<p>Launched in 2016 as a <a href="https://www.benzinga.com/topic/bnpl">buy now pay later (BNPL)</a> startup, the digital payment platform has excelled in providing consumers with flexible payment options for their purchases.&nbsp;</p>
<p>Achieving its first quarter of profitability in November 2022, Sezzle has an <a href="https://www.nasdaq.com/articles/top-5-nasdaq-fintech-stocks-updated-january-2025">estimated 529,000 active subscribers</a> and has generated $8.1 billion in merchant sales since its launch alongside 15 million completed sign-ups.&nbsp;</p>
<p>The stock went public in August 2023, and in its first calendar year of public trading in 2024 SEZL rallied more than 1,250%.&nbsp;</p>
<p>Sezzle's Q3 2024 earnings showed impressive revenue growth of <a href="https://www.stocktitan.net/news/SEZL/sezzle-reports-third-quarter-2024-46m3beg7flpr.html">71.3% year-over-year</a> to $70.0 million, underlining 2024's role as a breakout year for the stock. If it can nurture its increasing flows of custom, last year's performance could be a springboard for future outperformance as the cost-of-living could see more US consumers turning to <a href="https://www.benzinga.com/fintech/24/10/41385123/apple-pay-expands-buy-now-pay-later-with-affirm-adds-support-for-third-party-browsers-and-more">BNPL</a> to manage their finances.&nbsp;</p>
<h2 class="wp-block-heading">Future-Proofing Your Portfolio</h2>
<p>The sustained rise of fintech stocks is showing no signs of slowing and could be an excellent option for investors seeking to support their portfolios with strong growth stocks from the finance technology sector.&nbsp;</p>
<p>As an industry that's rapidly embracing new innovations, the fintech landscape can change at a rapid pace, so it's important to constantly audit your holdings to ensure that your chosen stocks still possess the fundamentals to ride the sector's boom period without any nasty surprises in the future.</p>


PYPL

SEZL

SOFI

The Future of Finance: 3 Fintech Stocks Set to Take Wall Street by Storm in 2025

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Deere</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DE, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Deere.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 11 are puts, for a total amount of $709,785, and 8 are calls, for a total amount of $1,590,340.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $550.0 for Deere over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Deere's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Deere's whale trades within a strike price range from $400.0 to $550.0 in the last 30 days. </p>
<h3>Deere 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737665185_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.5</td>
<td>$11.0</td>
<td>$11.65</td>
<td>$530.00</td>
<td>$932.0K</td>
<td align="right">87</td>
<td align="right">806</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$53.75</td>
<td>$50.05</td>
<td>$51.9</td>
<td>$440.00</td>
<td>$389.2K</td>
<td align="right">160</td>
<td align="right">0</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.95</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$400.00</td>
<td>$165.0K</td>
<td align="right">398</td>
<td align="right">116</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$22.45</td>
<td>$21.9</td>
<td>$22.17</td>
<td>$480.00</td>
<td>$102.0K</td>
<td align="right">74</td>
<td align="right">284</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$23.0</td>
<td>$22.1</td>
<td>$22.49</td>
<td>$480.00</td>
<td>$68.7K</td>
<td align="right">74</td>
<td align="right">219</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<p>Following our analysis of the options activities associated with Deere, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Deere</h3>
<ul>
<li>With a trading volume of 1,268,484, the price of DE is up by 3.09%, reaching $473.94.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>What The Experts Say On Deere</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $450.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Deere, targeting a price of $430.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Deere, maintaining a target price of $470. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Deere, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Unpacking the Latest Options Trading Trends in Deere

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Tripadvisor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TRIP, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for <strong>Tripadvisor</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 58% bullish and 33%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $26,242, and 11, calls, for a total amount of $475,703.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $22.0 for Tripadvisor over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Tripadvisor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tripadvisor's whale trades within a strike price range from $15.0 to $22.0 in the last 30 days. </p>
<h3>Tripadvisor Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737665180_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/31/25</td>
<td>$0.7</td>
<td>$0.65</td>
<td>$0.65</td>
<td>$16.50</td>
<td>$110.1K</td>
<td>48</td>
<td>5.5K</td>
</tr>
<tr>
<td>TRIP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$3.6</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$22.00</td>
<td>$77.5K</td>
<td>46</td>
<td>409</td>
</tr>
<tr>
<td>TRIP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.2</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$21.00</td>
<td>$51.7K</td>
<td>1.0K</td>
<td>848</td>
</tr>
<tr>
<td>TRIP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$20.00</td>
<td>$34.1K</td>
<td>541</td>
<td>88</td>
</tr>
<tr>
<td>TRIP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.1</td>
<td>$1.05</td>
<td>$1.05</td>
<td>$18.00</td>
<td>$31.8K</td>
<td>3.0K</td>
<td>1.7K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tripadvisor</h3>
<p>Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2023, 58% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 41% of sales in 2023, and TheFork, its dining brand, represented 9% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).</p>
<p>In light of the recent options history for Tripadvisor, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Tripadvisor</h3>
<ul>
<li>With a trading volume of 5,614,695, the price of TRIP is up by 2.22%, reaching $16.09.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 20 days from now.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Tripadvisor, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


TRIP

Looking At Tripadvisor's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Netflix</strong>.</p>
<p>Looking at options history for Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) we detected 239 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 39% with bearish.</p>
<p>From the overall spotted trades, 55 are puts, for a total amount of $2,536,654 and 184, calls, for a total amount of $16,016,932.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $1400.0 for Netflix over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Netflix's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Netflix's significant trades, within a strike price range of $10.0 to $1400.0, over the past month.</p>
<h3>Netflix 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737665175_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$209.4</td>
<td>$206.45</td>
<td>$207.95</td>
<td>$1030.00</td>
<td>$353.5K</td>
<td>42</td>
<td>34</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$209.4</td>
<td>$205.1</td>
<td>$207.35</td>
<td>$1030.00</td>
<td>$290.2K</td>
<td>42</td>
<td>17</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$580.0</td>
<td>$580.0</td>
<td>$580.0</td>
<td>$420.00</td>
<td>$290.0K</td>
<td>264</td>
<td>5</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$556.05</td>
<td>$553.15</td>
<td>$555.0</td>
<td>$430.00</td>
<td>$277.5K</td>
<td>37</td>
<td>5</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/24/25</td>
<td>$16.1</td>
<td>$15.5</td>
<td>$15.82</td>
<td>$970.00</td>
<td>$269.5K</td>
<td>1.7K</td>
<td>5.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Netflix</h3>
<p>Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.</p>
<p>Following our analysis of the options activities associated with Netflix, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Netflix Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,450,329, the NFLX's price is up by 2.73%, now at $980.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Netflix</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1071.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Neutral rating on Netflix with a target price of $680.<br />
&#x2A; An analyst from Needham persists with their Buy rating on Netflix, maintaining a target price of $1150.<br />
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $1175.<br />
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $1100.<br />
&#x2A; An analyst from Pivotal Research has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1250. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Netflix with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


NFLX

Looking At Netflix's Recent Unusual Options Activity

<p>AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 3.49% on an annualized basis producing an average annual return of 15.25%. Currently, AECOM has a market capitalization of $14.67 billion. </p>
<p><strong>Buying $1000 In ACM:</strong> If an investor had bought $1000 of ACM stock 10 years ago, it would be worth <strong>$4,068.82</strong> today based on a price of $110.60 for ACM at the time of writing.</p>
<h3>AECOM's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737665140_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning AECOM Stock In The Last 10 Years

<p><strong>Hyundai Motor Co., Ltd.</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>) disclosed that it sold 1.07 million vehicles globally in the fourth quarter, down 2.2% year-over-year.</p>
<p>Sales in Korea declined 4.6% 189,405 units, owing to slow demand and supply chain disruptions on heavy snowfall, while sales in markets outside of Korea fell 1.6% Y/Y to 876,834 <a target="_blank" href="https://www.hyundai.com/worldwide/en/newsroom/detail/0000000897" rel="noreferrer noopener">units</a> in fourth quarter.</p>
<p>In fourth quarter, global electrified vehicle sales (including commercial vehicles) rose 21% to 209,641 units, thanks to sales growth in the North American region. EVs accounted for 53,035 units, while hybrids (HEVs) accounted for 145,732 units.</p>
<p>In the fourth quarter, operating profit dipped 17.2% to KRW 2.82 trillion (~$1.9 billion) due to increased sales warranty provision resulting from a weaker KRW and higher incentives.</p>
<p>Revenue increased 11.9% Y/Y to KRW 46.62 trillion in the fourth quarter, with an operating profit margin of 6.1%.</p>
<p>In the fourth quarter, the company witnessed a net profit (including non-controlling interest) of KRW 2.47 trillion (+12.3% Y/Y).</p>
<p>Overall, the company sold 4.14 million vehicles worldwide in 2024, down 1.8% from 2023, with revenue rising 7.7% to KRW 175.2 trillion. For 2024, the company sold 757,191 electrified models (+8.9% Y/Y).</p>
<p>Operating profit in 2024 declined 5.9% to KRW 14.24 trillion, with an operating profit margin of 8.1%. Hyundai Motor saw a net profit of KRW 13.23 trillion (+7.8% Y/Y) in 2024.</p>
<p>Hyundai Motor plans to pay a year-end dividend of KRW 6,000 per common share, resulting in total payout of KRW 12,000 per common share for 2024.</p>
<p><strong>Outlook: </strong>Hyundai Motor expects consolidated revenue growth of 3%–4%, operating profit margin of 7%–8% and total vehicle sales exceeding <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">4.17 million units for 2025</a>.</p>
<p>The automaker plans investments of KRW 16.9 trillion for 2025, including KRW 8.6 trillion in capital expenditure, KRW 6.7 trillion in R&amp;D, and KRW 1.6 trillion in strategic investments.</p>
<p>In another development, Hyundai Motor is in talks with <strong>General Motors Company</strong> to supply commercial electric vehicles, as it anticipates sales growth to slow by half this year amid weakening demand, reported Reuters.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/node/42993822" target="_blank" rel="noreferrer noopener">South Korea&#8217;s Hyundai, Kia Collectively Sold More EVs In US Than Ford In 2024</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Earnings

Equities

Large Cap

HYMTF

Hyundai Clocks Mixed Q4: Revenue Climbs 12% While Operating Profit Slips On Warranty Costs

<p><strong>American Express Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) will be reporting its fourth-quarter earnings on Friday. Wall Street expects $3.04 in EPS and $17.16 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=AXP" target="_blank" rel="noreferrer noopener"> before market hours</a>.</p>
<p>The stock is up 75.61% over the past year, 9.14% YTD. During Thursday&#8217;s trading session, American Express stock reached a new 52-week high of $326.27, further solidifying its upward momentum ahead of the earnings report.</p>
<p>Let&#8217;s look at what the charts indicate for American Express stock and how the stock currently maps against Wall Street estimates.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/news/25/01/43066032/heres-how-much-you-would-have-made-owning-american-express-stock-in-the-last-5-years">Here&#8217;s How Much You Would Have Made Owning American Express Stock In The Last 5 Years</a></strong></p>
<h2 class="wp-block-heading">AXP Stock Chart Strongly Bullish Ahead Of Q4 Earnings</h2>
<p>AXP stock is demonstrating a strongly bullish trend, with its share price of $322.25 trading above key moving averages. </p>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23131630/Screenshot-2025-01-23-at-6.48.23-PM.png" alt="" class="wp-image-747509" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23131630/Screenshot-2025-01-23-at-6.48.23-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23131630/Screenshot-2025-01-23-at-6.48.23-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure></p>
<p><em><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>AXP stock remains above its eight-day ($312.02), 20-day ($304.92) and 50-day ($300.05) simple moving averages, reinforcing sustained buying pressure. Additionally, AXP stock is well above its 200-day SMA of $260.44, a strong long-term bullish indicator. </p>
<p>The MACD (moving average convergence/divergence) reading of 5.63 suggests upward momentum remains intact, while the RSI (relative strength index) at 69.62 indicates AXP stock is approaching overbought levels.</p>
<p>Investors may see continued upside as bullish signals persist, though a short-term consolidation could present better entry opportunities.</p>
<h2 class="wp-block-heading">American Express Analysts See Limited Upside</h2>
<p><strong>Ratings &amp; Consensus Estimates:</strong><a href="https://www.benzinga.com/quote/AXP/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on American Express stock stands at Neutral with a price target of $251.57. The latest analyst ratings from JPMorgan, UBS and Truist Securities imply a 0.12% upside for American Express stock with a $325.67 average price target.</p>
<p><strong>AXP</strong> <strong>Price Action: </strong>American Express stock was up 0.5% at $323.89 at last check Thursday.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43086592/financial-crime-weekly-american-express-pays-108-million-to-settle-deceptive-marketing-charges-vanguard-group-pays-106-million-for-violations">Financial Crime Weekly: American Express Pays $108 Million To Settle Deceptive Marketing Charges, Vanguard Group Pays $106 Million For Violations</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Technicals

Previews

American Express Stock Climbs Ahead Of Earnings, Signals Show Potential Cooling

<p><a href="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view" title="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view">https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view</a></p>


Contracts

CHRS

Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

WIIM

shares of nuclear stocks are trading higher amid recent reports of Santee Cooper seeking buyers to revive nuclear reaction construction in South Carolina.

Top-rated smaller tech stocks after sector's banner 2024

Mag 7? More like 'Mag 1' as Nvidia dominates the megacap club in 2024

Data center infrastructure revenue to reach $282B in 2024, capacity to triple by 2030

The top 10 private equity data center deals of 2024

Stock market's big battle this week: Yields 1, AI 0

Freaky Friday

Oppenheimer Asset Management - Market is supported by bulls and economic expansion despite recent declines

Tech sector struggles to start 2025, but these 10 stocks shine with Buy ratings

FTC examines AI deals between Microsoft & OpenAI, Amazon, Google & Anthropic

BofA survey reveals an optimistic view for 2025 and focus on healthcare and staples

Comments

Fidelity MSCI Information Technology Index ETF

Noticias

Últimas noticias sobre Fidelity MSCI Information Technology Index ETF (ARCA:FTEC)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL